AdipoLABs launches ‘high-frequency hyperthermia cancer treatment device’ in Malaysia

(Photo from left) Malaysian Minister of Health and Welfare (Datuk James Ratib), Cyberjaya University Chairman (KALAIARASU MALAIYANDI), and AdipoLABs CEO Han Sung-ho are taking a commemorative photo at the REMISSION 1℃ launching event. / Photo provided by AdipoLABs

AdipoLABs (CEO Han Sung-ho) announced on the 19th that the company has launched 'REMISSION 1℃', a hyperthermia cancer treatment device developed by the company, into the Malaysian market.

At the recent local launching event of REMISSION 1℃ held in Kota Kinabalu, Sabah, Malaysia, the Malaysian Minister of Health and Welfare (Datuk James Ratib), Malaysia Cyberjaya University Chairman (KALAIARASU MALAIYANDI), members of Malaysia Pink Ribbon (Malaysia Cancer Support Association) and about 200 medical staff came together.

Malaysia's Minister of Health and Welfare delivered a message at this event that a new horizon was opened for full-scale cancer treatment and pain treatment in Malaysia. “This will be an opportunity to advance healthcare solutions and raise awareness of new cancer treatment modalities,” she said in her congratulatory address. “It is a testament to our commitment to providing cutting-edge solutions, especially to the Han community in Sabah.” She also added, “This is an exemplary case in which Korean and Malaysian oncologists jointly conduct the project.”

The minister's remarks are interpreted as a reference to the case of the agreement between AdipoLABs and Cyberjaya University. Cyberjaya University is a comprehensive university located in Putrajaya City, Malaysia and is called one of the prestigious universities. This year, the university signed an MOU (business agreement) with AdipoLABs and has continued academic cooperation related to cancer treatment. The school has also collaborated for the clinical use of REMISSION 1℃.

AdipoLABs plans to promote ‘REMISSION 1℃’ locally through various channels other than this Malaysia launching event. An example is the '5th International Virus Research Alliance (IVRA) Conference' being held on November 25th. About 500 medical officials from overseas, including Malaysia, India, Singapore, and Romania, will gather to hold an international academic conference. In Korea alone, about 50 people, including medical staff, will participate.

IVRA is a medical organization formed by domestic and foreign researchers to treat the virus during the COVID-19 pandemic. Recently, the company has focused on cancer treatment and sharing the effects of clinical treatment.

Han Sung-ho, CEO of AdipoLABs, said, “The effectiveness of the high-frequency hyperthermia cancer treatment device of Remission 1℃ is showing clinical effectiveness both at home and abroad.” He added, “We will do our best to give hope to all those suffering from cancer not only in Korea but also around the world.” He said.